South Korean biopharmaceutical company Samsung Bioepis Co Ltd announced on Wednesday that it will take full commercial responsibility for BYOOVIZ (ranibizumab) in Europe from January 2026, following the transfer of rights from Biogen Inc (Nasdaq:BIIB).

The change follows an Asset Purchase Agreement covering BYOOVIZ, a biosimilar referencing Lucentis, and OPUVIZ (aflibercept), a biosimilar referencing Eylea.

Approved by the European Commission in August 2021 as Europe's first ophthalmology biosimilar, BYOOVIZ treats conditions including neovascular (wet) age-related macular degeneration (AMD), macular oedema following retinal vein occlusion (RVO), and myopic choroidal neovascularisation (mCNV). The therapy has been commercially available in several European markets since March 2023.

OPUVIZ received European Commission approval in November 2024 and UK Medicines and Healthcare products Regulatory Agency (MHRA) authorisation in April 2025 for multiple retinal conditions. Its European launch will occur after relevant Eylea patents expire or are revoked.

Samsung Bioepis said it will collaborate with Biogen to ensure a smooth transition and reaffirmed its commitment to expanding biosimilar access across Europe.